Biochemist. Fulbright Scholar. Stanford postdoc. Genome Compiler founder. Twist Bioscience exit. Tech.Bio. General Partner at NFX leading NFX Bio. Co-founder of Renewal Bio - building synthetic embryo tech to end aging. Mentor to 100+ biotech startups. Loud advocate for living to 160.
He wrote his PhD dissertation on membrane protein complexes involved in bio-energetics. Nobody outside Tel Aviv University read it. Then he went to Stanford on a Fulbright fellowship, worked in a neuroscience lab, graduated from Singularity University in 2011, and decided the most powerful technology on earth was sitting in a laboratory, unmonetized, waiting for someone to build the software layer on top of it.
That someone was Omri Amirav-Drory. And the software was Genome Compiler - essentially AutoCAD for DNA. Scientists could design biological sequences, debug them, compile them, collaborate on them, the same way engineers had been designing circuit boards for thirty years. The pitch was almost insultingly obvious in retrospect. At the time, it was considered deeply weird.
Twist Bioscience acquired Genome Compiler in 2016. Twist is now a $2.5 billion company on the NASDAQ. Omri stayed on as Head of Corporate Development for nearly three years, then did what operators-turned-investors usually do: he started writing checks.
Biology is the most advanced technology on earth. The only thing missing was software engineers who believed it.
- Omri Amirav-DroryHis pre-seed fund Tech.Bio caught Mammoth Biosciences before anyone was saying "CRISPR diagnostics" in polite company. It found Immunai when AI-powered immune mapping sounded like a research poster, not a company. Then NFX - a $1.4 billion fund known for early bets on DoorDash and Lyft - came calling. They needed someone who could sit across from a scientist-founder and actually understand what was in the vial.
At NFX, Omri leads NFX Bio. The thesis is straightforward: scientist-founders are systematically undervalued. They have grit - anyone who survives a PhD program has demonstrated an unusual tolerance for multi-year, often fruitless, high-stakes work. They have domain expertise that cannot be purchased. And they care, in the way that people who've spent a decade on a problem care, differently than people who picked a sector from a McKinsey slide deck.
But Omri doesn't just fund companies. He's been known to step in as acting CEO during incubation phases - an almost unheard-of level of operator involvement for a VC. He sits on more than fifteen boards. He has published over forty long-form articles on the NFX platform. At conferences, he doesn't do keynotes that end in "and that's why we're excited about the space." He publishes frameworks and tells founders what he actually looks for.
And then there's Renewal Bio.
"The last problem for AI to solve is health. Everything else is practice." - Omri Amirav-Drory
While running NFX Bio - which involves managing boards, sourcing deals, publishing essays, and occasionally acting as interim CEO - Omri also co-founded Renewal Bio alongside Prof. Jacob Hanna of the Weizmann Institute of Science.
The company is building what it calls "stem broids": synthetic embryo-like structures derived from stem cells, without sperm, eggs, or a uterus. The vision is clean and unsettling in equal measure: use these synthetic structures to grow young, genetically identical tissue replacements for aging bodies. Bone marrow. Liver cells. Eventually, neural tissue.
This is not distant science fiction. Hanna's lab at Weizmann has published in Nature. The science is real. Omri is building the company around it while simultaneously making pre-seed bets across fifteen other biotech startups.
The argument for longevity investment, as Omri frames it: aging is the root cause behind roughly nine of the ten deadliest diseases. Fix aging and you don't fight individual diseases one at a time - you remove the soil they grow in.
Most VCs claim to have proprietary frameworks. Most of those frameworks are retrospective rationalizations. This one is actually used to make decisions - and has been stated publicly, repeatedly, with specifics.
On the question of evaluating first-time versus repeat founders: he applies the same criteria. What matters is whether the founder thinks about their mission constantly - whether it keeps them up at night, whether they'd be doing this regardless of the money. Lab grit is the most honest signal: anyone who spent years repeating experiments that didn't work, pivoting their hypothesis, and defending their conclusions to a skeptical committee has already done the thing most startup founders find hardest.
Stem cell-derived synthetic embryo technology for longevity and regenerative medicine. Co-founded with Weizmann Institute's Prof. Jacob Hanna.
Physiologically accurate human tissue models - a bioplatform for drug discovery that actually mirrors human biology.
A single elegant platform with ambitions to target 90% of cancers. One of Omri's headline portfolio bets at NFX Bio.
Transcription factor drug discovery. Targeting the proteins most drugs can't reach - historically the "undruggable" class.
Universal flu vaccine. Received $37M in financing and brought a universal influenza candidate to clinic. A landmark for Omri's portfolio.
Lipid nanoparticle delivery technology - the vehicle problem for the next generation of RNA and gene therapies.
CRISPR-based diagnostics. An early Tech.Bio bet that grew into one of the marquee names in CRISPR applications.
AI-powered immune system mapping. Another pre-NFX bet that proved Omri's thesis on scientist-founders early.
Expanding gene therapy and gene editing portfolio - multiple board seats in precision medicine across rare disease and oncology.
"Ending involuntary death" is not a mission statement. It's a roadmap disguised as a slogan.
"Scientists make great founders because they care, they have deep scientific knowledge, and their experience in the lab proves that they have a lot of grit."
"Great IP and technology is not enough. The quality of the founding team is crucial."
"Why don't billionaires invest in longevity? It's the most important national strategy no one's talking about."
"Most venture investors miss exceptional opportunities by maintaining pessimistic outlooks. Conviction and optimism drive breakthrough investment decisions."